MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced the Company will present at the 2026 Jefferies Global Healthcare Conference being held in New York on June 2-4 2026.

Jefferies Global Healthcare Conference

Date: Thursday, June 4, 2026
Time: 3:45 PM ET
Format: Corporate Presentation

If you are interested in arranging a 1×1 meeting with management, please contact your conference representative.

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a focus on preeclampsia, fetal growth restriction and acute ischemic stroke. DiaMedica’s lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke, preeclampsia and other vascular diseases. For more information visit the Company’s website at www.diamedica.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260527840935/en/

Scott Kellen

Chief Financial Officer

Phone: (763) 496-5118

[email protected]

For Investor Inquiries:

Mike Moyer

Managing Director, LifeSci Advisors, LLC

Phone: (617) 308-4306

[email protected]

Media Contact:

Madelin Hawtin

LifeSci Communications

[email protected]

Source: DiaMedica Therapeutics Inc.